BergstromJ.Uremic toxins. In: Replacement of renal function by dialysis, DrukkerW., ParsonsF.M., MaherJ.F. eds. The Hague: Martinus Nijhoff1978; 368–72.
2.
BurzynskiE.Bound amino acids in serum of patients with chronic renal insufficiency.Clin Chim Acta1969; 25: 231–7.
3.
AdamJ., DzurikR., ValovicovaE.Ninhydrin-positive substances in serum and urine of patients with chronic uraemia.Clin Chim Acta1972; 36: 241–5.
4.
BabbA.L., FarrellP.C., UvelliD.A., ScribnerB.M.Hemodialysis evaluation by examination of solute molecular weight spectra: implications for the square meter-hour hypothesis.Trans Am Soc Artif Organs1972; 18: 98–105.
5.
FurstP., BergstromJ., GordonA.Separation of peptides of “middle molecular weight from biological fluids in patients with uremia.Kidney Int1975; 7: 272–5.
6.
Funk-BrentanoJ.L., ManN.K., SausseA.Characterization of a 1100-1300 MW uremic neurotoxin.Trans Am Soc Artif Intern Organs1976; 22: 163–7.
7.
HanickiZ., Sarnecka-KellerM., KleinA., SlizowskaK.Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. I. Preliminary characteristics.Clin Chim Acta1974; 54: 47–54.
8.
KleinA., Sarnecka-KellerM., HanickiZ.Middle-sized ninhydrin-positive molecules in uremic patients treated by repeated haemodialysis. II Chief peptide constituents of the fraction.Clin Chim Acta1978; 90: 7–11.
9.
ZimmermanL., BaldestenA., BergstromJ., FurstP.Isotachophoretic separation of middle molecule peptides in uremic body fluids.Clin Nephrol1980; 13: 183–8.
10.
GalliceP., FournierN., CrevatA., BriotM., FrayssinetR., MurisascoA.Separation of one middle uremic middle molecules fraction by high performance liquid chromatography.Kidney Int1983; 23: 764–6.
11.
MenyhartJ., GrofJ.Many hitherto unknown peptides are principal constituents of uremic middle molecules.Clin Chem1981; 27: 1712–6.
12.
ShaykhM., DubinA., DuneaG., MamdaniB., AhmedS.Separation, isolation and amino acid composition of uremic peptides.Clin Physiol Biochem1984; 2: 1–13.
13.
AsabaH., AlverstrandA., BergstromJ., FurstP., YanielV.Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistry.Clin Neph1982; 17(2): 90–5.
14.
AsabaH., AlverstrandA., FurstP., BergstromJ.Clinical implications of uremic middle molecules in regular hemodialysis patients.Clin Neph1983; 19(4): 179–87.
15.
ZimmermanL., JornvallH., BergstromJ.Characterization of a double conjugate in uremic body fluids.FEBS Lett1981; 129: 237–40.
16.
GalliceP., MontiJ.P., CrevatA., DurandC., MurisascoA.Identification by nuclear magnetic resonance and mass spectrometry of an endogenous compound in normal urine and uremic plasma.Clin Chem1985; 31: 30–4.
17.
MontiJ.P., GalliceP., CrevatA., MurisascoA.Identification by nuclear magnetic resonance and mass spectrometry of a glucuronic acid conjugate of o-hydroxy-benzoic acid in normal urine and uremic plasma.Clin Chem1985: 31(10): 1640–3.
18.
ChapmanG.V., WardR.A., FarrelP.C.Separation and quantification of the “middle molecules” in uremia.Kidney Int1980; 17: 82–8.
19.
ContrerasP., LaterR., NavarroJ., TourainJ.L., FreyriaA.M., TraegerJ.Molecules in the middle molecular weight range.Nephron1982; 32: 193–201.
SchootsA., MikkersF., CramersC., RingoirS.Profiling of uremic serum by high resolution gas chromatography, EI/CI mass spectrometry.J Chromatogr1977; 143: 247–57.
22.
SchootsA.C., MikkersF.E.P., ClaessensH.A., SmetR.D., LandschootN.V., RingoirS.M.G.Characterization of uremic middle molecular fractions by gas chromatography.Clin Chem1982; 28: 45–9.
23.
AbikoT., KumikawaM., IshizakiM., TakahashiH., SekinoH.Identification and synthesis of a tripeptide in ecum fluid of an uremic patient.Biochem Biophys Res Commun1978; 83: 357–64.
24.
AbikoT., KumikawaM., HiguchiH., SekinoH.Identification and synthesis of a heptapeptide in uremic fluid.Biochem Biophys Res Commun1978; 84: 184–94.
25.
AbikoT., OnoderaI., SekinoH.Isolation, structures and biological activity of the Trp-containing pentapeptide from uremic fluid.Biochem Biophys Res Commun1979; 89: 813–71.
26.
MabuchiH., NakahashiH.Medium-sized peptides in the blood of patients with uremia.Nephron1983; 3: 232–7.
27.
MabuchiH., NakahashiH.Analysis of middle molecular peptides in normal and uremic body fluids by high-performance gel chromatography.J Chromatogr1981; 224: 322–6.
KaplanB., GotfriedM., RavidM.Amino acid containing compounds in uremic serum-search for middle molecules by high performance liquid chromatography.Clin Neph1986; 26(2): 66–71.
30.
KaplanB., GotfriedM., CojocaruM., PrasM., RavidM.Bound amino acids in uremic sera: search for peptidic middle molecules by preparative polyacrylamide gel electrophoresis and high performance liquid chromatography.Clin Chem Acta1989; 185: 119–30.
31.
HeidlandA., HorlW.H., HellerN., HeineH., NeumannS., HeidbredeE.Proteolytic enzymes and catabolism: Enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis.Kidney Int1983; 24(suppl 16): S27–S36.
32.
GutierrezA., AlverstrandA., WahrenJ., BergstromJ.Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans.Kidney Int1990; 38(3): 487–94.
